Iressa NDA Awaits CMC Data; Oncology Response Rates Under Scrutiny At FDA
Executive Summary
FDA is looking carefully at response rates in assessing whether an endpoint demonstrates clinical benefit in oncology trials, Oncologic Drug Products Division Director Richard Pazdur, MD, said during the American Society of Clinical Oncology meeting in Orlando May 21
You may also be interested in...
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
FDA is understood to be considering the design of OSI/Genentech/Roche's Tarceva Phase III trial in refractory non-small cell lung cancer as a model for a postmarketing trial for AstraZeneca's Iressa
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
FDA is understood to be considering the design of OSI/Genentech/Roche's Tarceva Phase III trial in refractory non-small cell lung cancer as a model for a postmarketing trial for AstraZeneca's Iressa
AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail
AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call